Featured Courses
Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
- 1.00
Published:
Learning objectives
- Recall prevalence of patients who are statin uncontrolled/intolerant
- Define the additive benefit of combination treatment compared with statin intensification
- Name the non-statin LLTs offering proven CV protection
- Identifying patients with indication for novel non-statin therapy
- Initiate lipid-lowering strategies proven to lower future CV events
The Clinical Evidence Behind Pulse Field Ablation
- 1.00
Published:
Learning objectives
- Identify limitations of current ablation technologies
- Recall the advantages of pulse field ablation over other technologies
- Summarise the design, efficacy and safety findings of relevant clinical trial data evaluating the efficacy and safety of pulse field ablation technology
- Compare different PFA systems and emerging technologies
- Evaluate the evolving landscape of pulse field ablation technologies
TIO 2023 – Keynote & Debate
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
TIO 2023 – Balloon Revolution
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
TIO 2023 – Symposium: Lifetime Patient Management Greater Expectations: Is TAVI Rising to The Challenge?
- 1.00
Published:
Learning objectives
- Recall the latest data on durability and clinical outcomes for TAVI
- Understand how TAVI is advancing and become aware of future treatment options for lifetime management of patients with aortic valve disease
- Become more confident using TAVI in cases with complex anatomy
TIO 2023 – Atrioventricular Valve Replacement Beyond TEER?
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
Examining a Complex Heart Failure Case
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2.00
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Available Courses
Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
- 1.00
Published:
Learning objectives
- Recall prevalence of patients who are statin uncontrolled/intolerant
- Define the additive benefit of combination treatment compared with statin intensification
- Name the non-statin LLTs offering proven CV protection
- Identifying patients with indication for novel non-statin therapy
- Initiate lipid-lowering strategies proven to lower future CV events
Advances in Imaging: Optimising MR and CT in Daily Practice
- 2.00
Published:
Learning objectives
- Interpret existing clinical and meta data for use of pre-procedural, image-aided ablation in ventricular arrhythmias
- Identify where pre-procedural imaging may complement the current ablation workflow in ventricular arrhythmias
- Recall the clinical benefits of quantitative, MRI-based approaches to evaluate ischaemia
- Apply quantitative CMR imaging to complement existing procedural workflows in revascularisation procedures
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2.00
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Examining a Complex Heart Failure Case
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
Getting it Right First Time in Severe Aortic Stenosis - Key insights for Long Term Success
- 1.00
Published:
Learning objectives
- Recall current and predicted trends in TAVI with respect to preserving coronary access
- Consider determining factors for choosing valves in low risk populations
- Discuss solutions for maximising valve durability and haemodynamics and for treating degenerated TAVI
Heart Failure Management in a Changing Paradigm
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
HFO 2022 - Session 1.2 Practical Theory & Hot Topics: The Complex Patient
- 1.00
Published:
Learning objectives
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
HFO 2022 - Session 1.4 Practical Theory & Hot Topics: Transitioning Care and Monitoring Technology
- 1.00
Published:
Learning objectives
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
Most Recent
Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
- 1.00
Published:
Learning objectives
- Recall prevalence of patients who are statin uncontrolled/intolerant
- Define the additive benefit of combination treatment compared with statin intensification
- Name the non-statin LLTs offering proven CV protection
- Identifying patients with indication for novel non-statin therapy
- Initiate lipid-lowering strategies proven to lower future CV events
The Clinical Evidence Behind Pulse Field Ablation
- 1.00
Published:
Learning objectives
- Identify limitations of current ablation technologies
- Recall the advantages of pulse field ablation over other technologies
- Summarise the design, efficacy and safety findings of relevant clinical trial data evaluating the efficacy and safety of pulse field ablation technology
- Compare different PFA systems and emerging technologies
- Evaluate the evolving landscape of pulse field ablation technologies